LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 45

Search options

  1. Article: Effects of Single-Course Betamethasone on the Outcomes of Late Preterm Neonates.

    Rahimi, Farinaz / Safavi Ardabili, Nastaran / Asgharpoor, Homeira / Darsareh, Fatemeh

    Cureus

    2023  Volume 15, Issue 10, Page(s) e46672

    Abstract: Background Prenatal glucocorticoids are commonly used in pregnancies before 34 weeks of gestation in women at risk of preterm delivery; however, the effects of these drugs on late preterm infants (those born after the 34th week of pregnancy) are ... ...

    Abstract Background Prenatal glucocorticoids are commonly used in pregnancies before 34 weeks of gestation in women at risk of preterm delivery; however, the effects of these drugs on late preterm infants (those born after the 34th week of pregnancy) are controversial. As a result, we aimed to investigate the effect of a single course of betamethasone (two doses of betamethasone every 24 hours) on the neonatal outcome of late preterm births. Methods We retrospectively assessed all spontaneous late preterm births (34-36+6 weeks of gestation) at a tertiary hospital in Iran over a period of two and a half years. Exclusion criteria included multiple pregnancies, induced labor, and fetal malformations identified in sonograms. Neonatal outcome measures encompassed first and five-minute Apgar scores, respiratory distress syndrome, neonatal death, birth asphyxia, and the need for positive pressure ventilation, continuous positive airway pressure, tracheal intubation, and surfactant. Baseline characteristics, such as maternal age, parity, fetal gender, and high-risk pregnancy, were considered confounding variables. High-risk pregnancies were defined as any cases involving prolonged rupture of membranes or maternal comorbidities such as severe anemia, preeclampsia, diabetes, or COVID-19. Results During the study period, there were 830 spontaneous preterm births at our center. Of these, only 195 (23.5%) received complete doses of betamethasone. Low birth weight was more common in mothers who did not receive betamethasone compared to those who did (63.6% vs. 41.2%). The mean gestational age was lower in mothers who received betamethasone than in those who did not. Respiratory distress syndrome was more common in mothers who received betamethasone (P<0.001, RR 2.11, 95% CI (0.98-4.18)). However, after adjusting for confounding factors, such as gestational age and birth weight, betamethasone did not increase the risk of respiratory distress syndrome. Other adverse neonatal outcomes did not differ significantly. Conclusions There were no differences in neonatal outcomes between those who received betamethasone and those who did not.
    Language English
    Publishing date 2023-10-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.46672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Silencing of immune activation with methotrexate in patients with COVID-19.

    Safavi, Farinaz / Nath, Avindra

    Journal of the neurological sciences

    2020  Volume 415, Page(s) 116942

    MeSH term(s) Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammation/complications ; Inflammation/drug therapy ; Inflammation/immunology ; Methotrexate/therapeutic use ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; SARS-CoV-2
    Chemical Substances Immunosuppressive Agents ; Methotrexate (YL5FZ2Y5U1)
    Keywords covid19
    Language English
    Publishing date 2020-05-25
    Publishing country Netherlands
    Document type Editorial ; Research Support, N.I.H., Intramural
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2020.116942
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Silencing of immune activation with methotrexate in patients with COVID-19

    Safavi, Farinaz / Nath, Avindra

    Journal of the Neurological Sciences

    2020  Volume 415, Page(s) 116942

    Keywords Neurology ; Clinical Neurology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2020.116942
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Maternal and Neonatal Outcomes of Sub-clinical Hypothyroidism Treated With Levothyroxine in Pregnancy: A Retrospective Cohort Study.

    Safavi Ardabili, Nastaran / Rahimi, Farinaz / Ranjbar, Amene / Montazeri, Farideh / Darsareh, Fatemeh

    Cureus

    2023  Volume 15, Issue 9, Page(s) e45352

    Abstract: Introduction: The effect of sub-clinical hypothyroidism (SCH) in pregnancy has been controversial. Furthermore, the impact of levothyroxine replacement on improving outcomes in pregnant women with SCH is unknown. This study aimed to assess the maternal ... ...

    Abstract Introduction: The effect of sub-clinical hypothyroidism (SCH) in pregnancy has been controversial. Furthermore, the impact of levothyroxine replacement on improving outcomes in pregnant women with SCH is unknown. This study aimed to assess the maternal and neonatal outcomes of pregnant women with SCH who were treated with levothyroxine replacement.
    Methods: This retrospective chart review was conducted at a tertiary hospital in Iran between 2020 and 2022. All pregnant women who had given birth during the study period were recruited. Those who did not have thyroid function test results within 10-12 weeks, as well as those with SCH who did not have levothyroxine replacement, were excluded. The subjects were divided into two groups based on the 2017 American Thyroid Association (ATA) criteria: non-SCH (TSH values 0.27-2.5 mIU/L) and SCH (TSH values more than 4.0 mIU/L). The demographic, obstetric, maternal, and neonatal outcomes of both groups were compared. The Chi-square test was used to compare the categorical variables. Binary logistic regression was used to assess differences in categorical variables.
    Results: With a frequency of 10.5%, 935 women out of 8888 were diagnosed with SCH. In terms of age, educational level, living residency, medical insurance, access to prenatal care, and smoking status, there were no differences between the two groups. In terms of gestational age, parity, onset of labor, history of infertility, hypertension, cardiovascular disease, anemia, and overt diabetes, there were no differences between the two groups; however, gestational diabetes was more common in those with SCH. Compared with the non-SCH group, the prevalence and risks of gestational diabetes [19.8 vs. 14.2, odds ratio (OR) = 1.14, 95% confidence interval (CI) = 1.72-3.95] were significantly higher in the SCH group after controlling for confounding factors. There were no differences in neonatal outcomes between the two groups.
    Conclusions: Except for gestational diabetes, we found no significant adverse events in terms of maternal and neonatal outcomes among women with SCH who were treated with levothyroxine.
    Language English
    Publishing date 2023-09-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.45352
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Seeding Brain Protein Aggregation by SARS-CoV-2 as a Possible Long-Term Complication of COVID-19 Infection.

    Tavassoly, Omid / Safavi, Farinaz / Tavassoly, Iman

    ACS chemical neuroscience

    2020  Volume 11, Issue 22, Page(s) 3704–3706

    Abstract: Postinfection complications of coronavirus disease 2019 (COVID-19) are still unknown, and one of the long-term concerns in infected people are brain pathologies. The question is that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection ... ...

    Abstract Postinfection complications of coronavirus disease 2019 (COVID-19) are still unknown, and one of the long-term concerns in infected people are brain pathologies. The question is that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may be an environmental factor in accelerating the sporadic neurodegeneration in the infected population. In this regard, induction of protein aggregation in the brain by SARS-CoV-2 intact structure or a peptide derived from spike protein subunits needs to be considered in futures studies. In this paper, we discuss these possibilities using pieces of evidence from other viruses.
    MeSH term(s) Betacoronavirus/metabolism ; Brain/metabolism ; Brain/pathology ; Brain/virology ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Humans ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Protein Aggregates/physiology ; SARS-CoV-2 ; Time Factors
    Chemical Substances Protein Aggregates
    Keywords covid19
    Language English
    Publishing date 2020-11-04
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ISSN 1948-7193
    ISSN (online) 1948-7193
    DOI 10.1021/acschemneuro.0c00676
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.

    Tavassoly, Omid / Safavi, Farinaz / Tavassoly, Iman

    Molecular pharmacology

    2020  Volume 98, Issue 5, Page(s) 612–619

    Abstract: Heparan sulfate proteoglycans (HSPGs) are cell surface receptors that are involved in the cellular uptake of pathologic amyloid proteins and viruses, including the novel coronavirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Heparin ... ...

    Abstract Heparan sulfate proteoglycans (HSPGs) are cell surface receptors that are involved in the cellular uptake of pathologic amyloid proteins and viruses, including the novel coronavirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Heparin and heparan sulfate antagonize the binding of these pathogens to HSPGs and stop their cellular internalization, but the anticoagulant effect of these agents has been limiting their use in the treatment of viral infections. Heparin-binding peptides (HBPs) are suitable nonanticoagulant agents that are capable of antagonizing binding of heparin-binding pathogens to HSPGs. Here, we review and discuss the use of HBPs as viral uptake inhibitors and will address their benefits and limitations to treat viral infections. Furthermore, we will discuss a variant of these peptides that is in the clinic and can be considered as a novel therapy in coronavirus disease 2019 (COVID-19) infection. SIGNIFICANCE STATEMENT: The need to discover treatment modalities for COVID-19 is a necessity, and therapeutic interventions such as heparin-binding peptides (HBPs), which are used for other cases, can be beneficial based on their mechanisms of actions. In this paper, we have discussed the application of HBPs as viral uptake inhibitors in COVID-19 and explained possible mechanisms of actions and the therapeutic effects.
    MeSH term(s) Animals ; Antiviral Agents/chemistry ; Antiviral Agents/metabolism ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Betacoronavirus/physiology ; COVID-19 ; Coronavirus Infections/drug therapy ; Heparan Sulfate Proteoglycans/chemistry ; Heparan Sulfate Proteoglycans/metabolism ; Humans ; Pandemics ; Peptides/chemistry ; Peptides/metabolism ; Peptides/pharmacology ; Peptides/therapeutic use ; Pneumonia, Viral/drug therapy ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/metabolism ; Virus Internalization/drug effects
    Chemical Substances Antiviral Agents ; Heparan Sulfate Proteoglycans ; Peptides ; Spike Glycoprotein, Coronavirus ; spike glycoprotein, SARS-CoV
    Keywords covid19
    Language English
    Publishing date 2020-09-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 124034-1
    ISSN 1521-0111 ; 0026-895X
    ISSN (online) 1521-0111
    ISSN 0026-895X
    DOI 10.1124/molpharm.120.000098
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.

    Safavi, Farinaz / Nourbakhsh, Bardia / Azimi, Amir Reza

    Multiple sclerosis and related disorders

    2020  Volume 43, Page(s) 102195

    Abstract: Objective: To determine whether the course of COVID-19 is more severe in patients with MS and if MS disease-modifying treatments (DMTs) affect the risk of contracting the disease.: Methods: In a cross-sectional survey, data were collected by sending ... ...

    Abstract Objective: To determine whether the course of COVID-19 is more severe in patients with MS and if MS disease-modifying treatments (DMTs) affect the risk of contracting the disease.
    Methods: In a cross-sectional survey, data were collected by sending a questionnaire to 2000 patients with a demyelinating disease through an online portal system. Collected data included the current MS DMT and patient-reported disability level, history of recent sick contact, recent fever, respiratory symptoms, diagnosis with COVID-19, and the disposition after the diagnosis. We defined a COVID-19-suspect group as patients having fever and cough or fever and shortness of breath, or a presumptive diagnosis based on suggestive chest computed tomography. We calculated the proportion of COVID-19-suspect patients and compared their demographics, clinical characteristics, and DMT categories with the rest of survey-responders, using univariable and multivariable models.
    Results: Out of 712 patients, 34 (4.8%) fulfilled our criteria for being in the COVID-19-suspect group. Only two patients required hospitalization. No patient required intensive care. In a multivariable model, disease duration (p-value=0.017), DMT category (p-value=0.030), and history of sick contact (p-values<0.001) were associated with the risk of being in the COVID-19-suspect group. Being on B-cell depleting antibodies (as compared to non-cell depleting, non-cell trafficking inhibitor DMTs) was associated with a 2.6-fold increase in the risk of being in the COVID-19-suspect group. (RR: 3.55, 95%CI: 1.45, 8.68, p-value=0.005).
    Conclusions: The course of infection in patients with MS suspected of having COVID-19 was mild to moderate, and all patients had a full recovery. B-cell depleting antibodies may increase the susceptibility to contracting COVID-19.
    MeSH term(s) Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; B-Lymphocytes/immunology ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/epidemiology ; Coronavirus Infections/immunology ; Coronavirus Infections/physiopathology ; Cough ; Cross-Sectional Studies ; Crotonates/therapeutic use ; Dimethyl Fumarate/therapeutic use ; Disease Susceptibility ; Dyspnea ; Epidemics ; Female ; Fever ; Fingolimod Hydrochloride/therapeutic use ; Glatiramer Acetate/therapeutic use ; Hospitalization/statistics & numerical data ; Humans ; Immunocompromised Host/immunology ; Immunologic Factors/therapeutic use ; Intensive Care Units/statistics & numerical data ; Interferons/therapeutic use ; Iran/epidemiology ; Lung/diagnostic imaging ; Lymphocyte Depletion ; Male ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Chronic Progressive/drug therapy ; Multiple Sclerosis, Chronic Progressive/epidemiology ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/epidemiology ; Natalizumab/therapeutic use ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/immunology ; Pneumonia, Viral/physiopathology ; Rituximab/therapeutic use ; SARS-CoV-2 ; Severity of Illness Index ; Toluidines/therapeutic use ; Tomography, X-Ray Computed
    Chemical Substances Antibodies, Monoclonal, Humanized ; Crotonates ; Immunologic Factors ; Natalizumab ; Toluidines ; teriflunomide (1C058IKG3B) ; Rituximab (4F4X42SYQ6) ; Glatiramer Acetate (5M691HL4BO) ; Interferons (9008-11-1) ; ocrelizumab (A10SJL62JY) ; Dimethyl Fumarate (FO2303MNI2) ; Fingolimod Hydrochloride (G926EC510T)
    Keywords covid19
    Language English
    Publishing date 2020-05-13
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2020.102195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Seeding Brain Protein Aggregation by SARS-CoV-2 as a Possible Long-Term Complication of COVID-19 Infection

    Tavassoly, Omid / Safavi, Farinaz / Tavassoly, Iman

    ACS Chemical Neuroscience ; ISSN 1948-7193 1948-7193

    2020  

    Keywords Cell Biology ; Biochemistry ; Physiology ; Cognitive Neuroscience ; General Medicine ; covid19
    Language English
    Publisher American Chemical Society (ACS)
    Publishing country us
    Document type Article ; Online
    DOI 10.1021/acschemneuro.0c00676
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

    Safavi, Farinaz / Nourbakhsh, Bardia / Azimi, Amir Reza

    Multiple Sclerosis and Related Disorders

    2020  Volume 43, Page(s) 102195

    Keywords Neurology ; Clinical Neurology ; General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2020.102195
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top